Abstracts Archive - Page 831 of 2425 - ACR Meeting Abstracts

Abstract Number: 1089 • 2019 ACR/ARP Annual Meeting
Causes of Death in ANCA-Associated Vasculitis According to ANCA Type
Zachary Wallace¹, Xiaoqing Fu ¹, Tyler Harkness ¹, John Stone ², Yuqing Zhang ³ and Hyon K. Choi ³, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Survival has improved in ANCA-associated vasculitis (AAV) with evolving management strategies, but patients remain at an increased risk of death compared to the general…
Abstract Number: 1090 • 2019 ACR/ARP Annual Meeting
Identification of a Distinct Intestinal Behçet’s Disease Cluster in Japan: A Nationwide Retrospective Observational Study
Yutaro Soejima¹, Yohei Kirino ¹, Mitsuhiro Takeno ², Michiko Kurosawa ³, Ryusuke Yoshimi ¹, Nobuhisa Mizuki ⁴ and Hideaki Nakajima ¹, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Nippon Medical School, Tokyo, Japan, ³Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁴Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Background: Behçet’s disease (BD) patients with poor prognoses must be identified to receive individualized care. Purpose: This study aimed to identify a subgroup of…
Abstract Number: 1091 • 2019 ACR/ARP Annual Meeting
Risk of Preterm Birth by Timing of Lupus Diagnosis Among Women in the Georgia Lupus Registry
Meghan Angley¹, Penelope P. Howards ¹, Cristina Drenkard ¹ and S Sam Lim ¹, ¹Emory University, Atlanta, GA
Background/Purpose: Women with systemic lupus erythematosus (SLE) are at a greater risk of having a preterm birth than the general population. Most studies examine preterm…
Abstract Number: 1092 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Dose Adjustment Based on Patients’ Body Size in Low Dose Intravenous CYC Treatment for Rheumatic Diseases
Aiko Hirano¹, Takashi Kida ¹, Akiko Kasahara ¹, Aki Sakashita ¹, Tomoya Sagawa ¹, Shunya Kaneshita ¹, Takuya Inoue ¹, Kazuki Fujioka ¹, Wataru Fujii ¹, Makoto Wada ¹, Masataka Kohno ¹ and Yutaka Kawahito ¹, ¹Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Japan
Background/Purpose: Intravenous (IV) CYC in combination with glucocorticoids is a widely used induction therapy for severe cases of rheumatic diseases such as SLE, SSc, DM…
Abstract Number: 1093 • 2019 ACR/ARP Annual Meeting
The US Prevalence of Inflammatory Bowel Disease and Associated Axial Pain: Data from the National Health & Nutrition Examination Survey (NHANES)
Oleg Stens¹, Charles Dillon ², Frederick W. Miller ³ and Michael Weisman ⁴, ¹Harbor-UCLA Medical Center, Torrance, CA, ²National Institutes of Health, Bethesda, MD, ³NIEHS, NIH, Bethesda, MD, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Associations between ulcerative colitis (UC) and Crohn’s disease, known together as inflammatory bowel disease (IBD), with axial pain, inflammatory back pain (IBP) and spondyloarthritis…
Abstract Number: 1094 • 2019 ACR/ARP Annual Meeting
EULAR Points to Consider for the Development, Evaluation and Implementation of Mobile Health Applications for Self-management in Patients with Rheumatic and Musculoskeletal Diseases
Aurelie Najm¹, Elena Nikiphorou ², Marie Kostine ³, Christophe Richez ⁴, John Pauling ⁵, Axel Finckh ⁶, Valentin Ritschl ⁷, Petra Balazova ⁸, Simon Stones ⁹, zoltan Szekanecz ¹⁰, Yeliz Prior ¹¹, ANNAMARIA IAGNOCCO ¹², Sofia Ramiro ¹³, Francisca Sivera ¹⁴, Maxime Dougados ¹⁵, Loreto Carmona ¹⁶, Gerd Burmester ¹⁷, Dieter Wiek ¹⁸, Laure Gossec ¹⁹ and Francis Berenbaum ²⁰, ¹Nantes University Hospital, Nantes, France, ²King's College London, London, United Kingdom, ³Department of Rheumatology, Bordeaux, France, ⁴Deprtament of Rheumatology, Bordeaux, France, ⁵Department of Rheumatology, Royal National Hospital of Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, England, United Kingdom, ⁶Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland, ⁷Medical University of Vienna, Vienna, Austria, ⁸EULAR Young PARE, Zurich, Switzerland, ⁹University of Leeds, Leeds, United Kingdom, ¹⁰University of Debrecen, Debrecen, Hungary, ¹¹Centre for Health Sciences Research, University of Salford, Salford and Mid Cheshire NHS Foundation Trust Hospitals, Crewe, UK, Salford, United Kingdom, ¹²Academic Rheumatology Centre, Università degli Studi di Torino, TURIN, Italy, ¹³Leiden University Medical Centre, Leiden, Netherlands, ¹⁴Hospital General Universitario de Elda, Elda, Spain, ¹⁵Cochin Hospital, Paris, France, ¹⁶Instituto de Salud Musculoesquelética - Inmusc., Madrid, Spain, ¹⁷Charité—University Medicine Berlin, Berlin, Germany, ¹⁸patient research partner, Germany, Germany, Germany, ¹⁹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²⁰Sorbonne Université-Inserm CDR Saint-Antoine, AP-HP, Paris, France
Background/Purpose: In the expanding era of e-health, a wide range of mobile health applications (apps) have become available to enable people with rheumatic and musculoskeletal…
Abstract Number: 1095 • 2019 ACR/ARP Annual Meeting
The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis
Linh Truong¹, Nicole Ridolfi ², Eugenia Chen ² and Maida wong ³, ¹University of California, Irvine, San Diego, CA, ²University of California, Irvine, Orange, ³Tibor Rubin Veterans Affairs Medical Center, Long Beach
Background/Purpose: There is accumulating evidence demonstrating an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among the psoriatic arthritis (PsA) population. Yet, the relationship between immunosuppressive…
Abstract Number: 1096 • 2019 ACR/ARP Annual Meeting
Learning the Relationships Between Psoriatic Arthritis and a Patient’s History of Musculoskeletal Symptoms from Electronic Health Records Using Bayesian Networks
Amelia Green ¹, Theresa Smith ¹ and Neil McHugh¹, ¹University of Bath, Bath, England, United Kingdom
Background/Purpose: Electronic health records (EHRs) from large health care systems provide access to rich and comprehensive patient-specific information from many sources consisting of heterogeneous data…
Abstract Number: 1097 • 2019 ACR/ARP Annual Meeting
Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study
Lingyi Li¹, Na Lu ¹, Jacek Kopec ², John Esdaile ³, Hui Xie ⁴ and J. Antonio Avina-Zubieta ², ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁴Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are prescribed for the management of pain among patients with rheumatic diseases including systemic lupus erythematosus (SLE). However,…
Abstract Number: 1098 • 2019 ACR/ARP Annual Meeting
Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study
Melinda Kedves¹, Fruzsina Kósa ², Péter Takács ², Péter Kunovszki ², Jennifer Lofland ³ and György Nagy ⁴, ¹Hospital of Bács-Kiskun County, Department of Rheumatology, Kecskemét, Bacs-Kiskun, Hungary, ²Janssen, GCSO, Budapest, Budapest, Hungary, ³Janssen Scientific Affairs, LLC, Spring House, PA, ⁴Buda Hospital of the Hospitaller Order of Saint John of God, Department of Rheumatology, Budapest, Budapest, Hungary
Background/Purpose: There is little evidence in Hungary on the real incidence, prevalence and mortality of systemic lupus erythematosus (SLE) that is based on a robust…
Abstract Number: 1099 • 2019 ACR/ARP Annual Meeting
The Safety of Pulse Therapy- Systematic Review and Meta-analysis
Yonatan Edel¹, Tomer Avni ¹, Yair Molad ², daniel Shepshelovich ¹, shelley Reich ¹, Benaya Rozen-zvi ¹, Michal elbaz ³, leonard leibovici ³ and Anat Gafter-Gvili ¹, ¹Rabin Medical Center, petach tikva, HaMerkaz, Israel, ²Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, HaMerkaz, Israel, ³rabin Medical Center, petach tikva, Israel
Background/Purpose: Very high dose (or pulse) glucocorticoid treatment is widely used for autoimmune, inflammatory, infectious and other conditions. We aimed to amass all available evidence…
Abstract Number: 1100 • 2019 ACR/ARP Annual Meeting
Opioid Overdose Hospitalizations in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Christine Anastasiou¹, Jing Li ¹, Laura Trupin ², Gabriela Schmajuk ³ and Jinoos Yazdany ¹, ¹UCSF Division of Rheumatology, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) often suffer from both acute and chronic pain, and the prevalence of opioid medication…
Abstract Number: 1101 • 2019 ACR/ARP Annual Meeting
Development of an Algorithm to Identify Sjögren’s Syndrome Patients in the French National Healthcare Claims Database
Valérie Devauchelle Pensec¹, Laurent Chiche ², Joe Zhuo ³, Isabelle Lavrard ⁴, Guillaume Desjeux ⁵ and Raphaele Seror ⁶, ¹University Hospital of Brest, Brest, France, ²Hôpital Européen, Marseille, France, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Bristol-Myers Squibb, Rueil-Malmaison, France, ⁵E-health Services Sanoïa, Digital CRO, Gémenos, France, ⁶Hopitaux universitaires Paris Sud, Kremlin-Bicetre, France
Background/Purpose: Sjogren’s syndrome (SS) is a chronic autoimmune disease, consistingof primary SS (pSS) when it presents alone and secondary or associated SS whenaccompanied by other…
Abstract Number: 1102 • 2019 ACR/ARP Annual Meeting
Estimate of Prevalence of Secondary Distal Renal Tubular Acidosis Among Patients with Sjogren’s Syndrome and Systemic Lupus Erythematosus in a US Population with Employer-Sponsored Health Insurance
Gary Bryant¹, Linda Law ² and Josephine Li-McLeod ³, ¹University of Minnesota Medical School, Minneapolis, MN, ²Advicenne, Cincinnati, OH, ³Stratevi, Boston, MA
Background/Purpose: Distal renal tubular acidosis (dRTA) involves impairment in the distal tubule, leading to insufficient renal acid secretion, which can result in metabolic acidosis, hypokalemia,…
Abstract Number: 1103 • 2019 ACR/ARP Annual Meeting
Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE), Patient Healthcare Utilization and Characteristics by Major Health Insurance Types in the US
Yiting Wang¹, Laura Hester ¹, Jennifer Lofland ², Shawn Rose ³, Chetan Karyekar ⁴, Dave Kern ⁵, Margaret Blacketer ¹, Kourtney Davis ¹ and Kimberly Shields-Tuttle ⁶, ¹Janssen Research & Development, LLC, Titusville, ²Janssen Scientific Affairs, LLC, Spring House, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Global Services, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, Titusville, ⁶Janssen Research & Development, LLC, Spring House
Background/Purpose: One study estimated that between 161,000 and 322,000 people in the US had definite or probable SLE, based on data from the period of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].